Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) Invested Capital (2018 - 2026)

TransMedics has reported Invested Capital over the past 8 years, most recently at $483.1 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 111.33% year-over-year to $483.1 million; the TTM value through Dec 2025 reached $483.1 million, up 111.33%, while the annual FY2025 figure was $483.1 million, 111.33% up from the prior year.
  • Invested Capital for Q4 2025 was $483.1 million at TransMedics, up from $360.2 million in the prior quarter.
  • Over five years, Invested Capital peaked at $483.1 million in Q4 2025 and troughed at $50.9 million in Q2 2022.
  • A 5-year average of $181.8 million and a median of $173.4 million in 2022 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: tumbled 42.78% in 2022 and later surged 221.52% in 2023.
  • Year by year, Invested Capital stood at $67.9 million in 2021, then surged by 176.14% to $187.4 million in 2022, then dropped by 26.78% to $137.2 million in 2023, then soared by 66.62% to $228.6 million in 2024, then soared by 111.33% to $483.1 million in 2025.
  • Business Quant data shows Invested Capital for TMDX at $483.1 million in Q4 2025, $360.2 million in Q3 2025, and $318.1 million in Q2 2025.